Master the Dynamic Challenges of the Pharma Industry in 2023
The pharmaceutical industry faces complex regulatory challenges and scrutiny while striving to maintain patient safety and innovation. With disruptions caused by the pandemic and supply chain issues, traceability and transparency are increasingly important for quality control and regulatory compliance, necessitating standardized reporting mechanisms to build a resilient supply chain. This report addresses these challenges and aims to assist businesses in navigating the evolving regulatory landscape and mitigating emerging risks.
The European Commission’s proposed requirements for pharmaceutical companies in the EU aim to enhance accessibility and affordability of medicines. Compliance with these updates will require increased transparency and a focus on supply chain agility.
The pharma industry faces challenges due to overreliance on developing countries for ingredient supplies, with a high prevalence of counterfeit or substandard medical products.
Build a Resilient Pharma Future in Times of Disruption
Disruptions in concentrated markets, along with the need for comprehensive due diligence and third-party risk management, can significantly impact the supply chain. Additionally, ensuring drug safety in the cold chain and complying with traceability requirements pose further challenges for pharmaceutical companies.
ESG considerations are becoming a significant focus for the pharmaceutical industry in 2023, as public awareness of the industry’s environmental impact and social responsibilities increases, requiring companies to strengthen reporting, meet environmental benchmarks, scrutinize third parties, and enhance governance frameworks to ensure compliance with regulations and mitigate risks.
Learn about the industry’s evolving regulatory landscape, the importance of ESG considerations, supply chain vulnerabilities, and strategies for compliance and risk management.